Document is current
Any future updates will be listed below
-
Authors
Polk, Sarah E.
Öhman, Fredrik
Hassenstab, Jason
König, Alexandra
Papp, Kathryn V.
Schöll, Michael
Berron, David
-
Funding
Funding for this research was provided by:
EU Joint Programme – Neurodegenerative Disease Research (01ED2401, 01ED2401, 01ED2401, 01ED2401, 01ED2401)
NIH/NIA (1R01AG084017-01A1)
- License Information
-
More Information
Article History
Received: 25 September 2024
Accepted: 25 March 2025
First Online: 10 May 2025
Competing interests
: SEP and FÖ declare no competing interests. JH is a paid consultant for Eisai, AlzPath, Prothena. AK is an employee of ki:elements. KVP has served as a paid consultant for Novoic, Prothena, and Biogen and is on the advisory board for Cogstate. MS has served on advisory boards for Roche and Novo Nordisk, received speaker honoraria from Bioarctic, Eisai, Genentech, Lilly, Novo Nordisk and Roche and receives research support (to the institution) from Alzpath, Bioarctic, Novo Nordisk and Roche (outside scope of submitted work); he is a co-founder and shareholder of Centile Bioscience and serves as Associate Editor with Alzheimer’s Research & Therapy. DB is co-founder and shareholder of neotiv GmbH.
